The partnership will focus on therapies derived from biologics — cells, blood, enzymes, tissues, genes, or genetically engineered cells — for use in medicines. It will help Mayo Clinic and third-party biotechs to advance cell therapies into clinical trials.
The partners say the collaboration will help establish Rochester, Minnesota, as a center of excellence for biomanufacturing cell and regenerative technologies.
From biomanufacturing to business support
Resilience was founded in 2020 with a pledge to broaden access to complex medicines through innovations in technology-focused biomanufacturing. It is building a network of high-tech, end-to-end manufacturing solutions so that treatments can be made quickly, safely, and at scale.
In the new partnership, Resilience will collaborate with Mayo’s Center for Regenerative Medicine in Two Discovery Square, located within the research corridor of the Destination Medical Center economic development initiative in Rochester.
Resilience and Mayo will build embedded process and analytical development labs, as well as quality control labs. This “embedded” approach allows for closer proximity and collaboration to jointly develop and progress cell therapies and other advanced modalities into clinical care, say the partners.
The collaboration also aims to attract third-party biotech companies interested in sponsoring clinical trials for new therapeutics, as well as collaborating on their process and analytical development. It also wants to advance biologic discoveries towards early stage clinical trials.